Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $16.69, for a total transaction of $917,950.00. Following the completion of the transaction, the chief executive officer now owns 276,017 shares in the company, valued at approximately $4,606,723.73. This represents a 16.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Saurabh Saha also recently made the following trade(s):

• On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00.
• On Tuesday, January 21st, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.77, for a total transaction of $867,350.00.

Centessa Pharmaceuticals Trading Down 3.3 %

Shares of NASDAQ:CNTA opened at $15.75 on Monday. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09. The company’s 50 day moving average is $16.47 and its two-hundred day moving average is $16.41. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.08 billion, a PE ratio of -10.29 and a beta of 1.54.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Guggenheim restated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $26.00.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Large investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at approximately $2,834,000. Wellington Management Group LLP purchased a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at approximately $1,609,000. State Street Corp purchased a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at approximately $777,000. Ally Bridge Group NY LLC purchased a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at approximately $4,951,000. Finally, Lord Abbett & CO. LLC purchased a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at approximately $4,305,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.